222 related articles for article (PubMed ID: 30061887)
1. Glyco-Engineered Anti-Human Programmed Death-Ligand 1 Antibody Mediates Stronger CD8 T Cell Activation Than Its Normal Glycosylated and Non-Glycosylated Counterparts.
Goletz C; Lischke T; Harnack U; Schiele P; Danielczyk A; Rühmann J; Goletz S
Front Immunol; 2018; 9():1614. PubMed ID: 30061887
[TBL] [Abstract][Full Text] [Related]
2. Anti-Tumor Necrosis Factor With a Glyco-Engineered Fc-Region Has Increased Efficacy in Mice With Colitis.
Bloemendaal FM; Levin AD; Wildenberg ME; Koelink PJ; McRae BL; Salfeld J; Lum J; van der Neut Kolfschoten M; Claassens JW; Visser R; Bentlage A; D'Haens GRAM; Verbeek JS; Vidarsson G; van den Brink GR
Gastroenterology; 2017 Nov; 153(5):1351-1362.e4. PubMed ID: 28756234
[TBL] [Abstract][Full Text] [Related]
3. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody.
Stewart R; Morrow M; Hammond SA; Mulgrew K; Marcus D; Poon E; Watkins A; Mullins S; Chodorge M; Andrews J; Bannister D; Dick E; Crawford N; Parmentier J; Alimzhanov M; Babcook JS; Foltz IN; Buchanan A; Bedian V; Wilkinson RW; McCourt M
Cancer Immunol Res; 2015 Sep; 3(9):1052-62. PubMed ID: 25943534
[TBL] [Abstract][Full Text] [Related]
4. An Fc Double-Engineered CD20 Antibody with Enhanced Ability to Trigger Complement-Dependent Cytotoxicity and Antibody-Dependent Cell-Mediated Cytotoxicity.
Wirt T; Rosskopf S; Rösner T; Eichholz KM; Kahrs A; Lutz S; Kretschmer A; Valerius T; Klausz K; Otte A; Gramatzki M; Peipp M; Kellner C
Transfus Med Hemother; 2017 Sep; 44(5):292-300. PubMed ID: 29070974
[TBL] [Abstract][Full Text] [Related]
5. Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab.
Fujii R; Friedman ER; Richards J; Tsang KY; Heery CR; Schlom J; Hodge JW
Oncotarget; 2016 Jun; 7(23):33498-511. PubMed ID: 27172898
[TBL] [Abstract][Full Text] [Related]
6. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548
[TBL] [Abstract][Full Text] [Related]
7. The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells.
Estupina P; Fontayne A; Barret JM; Kersual N; Dubreuil O; Le Blay M; Pichard A; Jarlier M; Pugnière M; Chauvin M; Chardès T; Pouget JP; Deshayes E; Rossignol A; Abache T; de Romeuf C; Terrier A; Verhaeghe L; Gaucher C; Prost JF; Pèlegrin A; Navarro-Teulon I
Oncotarget; 2017 Jun; 8(23):37061-37079. PubMed ID: 28427157
[TBL] [Abstract][Full Text] [Related]
8. A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity.
Luan Y; Chai D; Peng J; Ma S; Wang M; Ma H; Li X; Fu S; Pan X; Wang X; Qin S; Xu T
Int Immunopharmacol; 2016 Feb; 31():248-56. PubMed ID: 26773772
[TBL] [Abstract][Full Text] [Related]
9. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer.
Brauner E; Gunda V; Vanden Borre P; Zurakowski D; Kim YS; Dennett KV; Amin S; Freeman GJ; Parangi S
Oncotarget; 2016 Mar; 7(13):17194-211. PubMed ID: 26943572
[TBL] [Abstract][Full Text] [Related]
10. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells.
Homma S; Hayashi K; Yoshida K; Sagawa Y; Kamata Y; Ito M
Int Immunopharmacol; 2018 Jan; 54():39-45. PubMed ID: 29100036
[TBL] [Abstract][Full Text] [Related]
11. Cbl-b Deficiency Mediates Resistance to Programmed Death-Ligand 1/Programmed Death-1 Regulation.
Fujiwara M; Anstadt EJ; Clark RB
Front Immunol; 2017; 8():42. PubMed ID: 28184224
[TBL] [Abstract][Full Text] [Related]
12. Improved effector functions of a therapeutic monoclonal Lewis Y-specific antibody by glycoform engineering.
Schuster M; Umana P; Ferrara C; Brünker P; Gerdes C; Waxenecker G; Wiederkum S; Schwager C; Loibner H; Himmler G; Mudde GC
Cancer Res; 2005 Sep; 65(17):7934-41. PubMed ID: 16140965
[TBL] [Abstract][Full Text] [Related]
13. Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies.
Satoh M; Iida S; Shitara K
Expert Opin Biol Ther; 2006 Nov; 6(11):1161-73. PubMed ID: 17049014
[TBL] [Abstract][Full Text] [Related]
14. Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events.
Huang Z; Pang X; Zhong T; Qu T; Chen N; Ma S; He X; Xia D; Wang M; Xia M; Li B
Front Immunol; 2022; 13():924542. PubMed ID: 35833116
[TBL] [Abstract][Full Text] [Related]
15. Roles of programmed death-1 (PD-1)/PD-1 ligands pathway in the development of murine acute myocarditis caused by coxsackievirus B3.
Seko Y; Yagita H; Okumura K; Azuma M; Nagai R
Cardiovasc Res; 2007 Jul; 75(1):158-67. PubMed ID: 17434153
[TBL] [Abstract][Full Text] [Related]
16. Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells.
Gibbons Johnson RM; Dong H
Front Immunol; 2017; 8():961. PubMed ID: 28848559
[TBL] [Abstract][Full Text] [Related]
17. Glycoengineered Monoclonal Antibodies with Homogeneous Glycan (M3, G0, G2, and A2) Using a Chemoenzymatic Approach Have Different Affinities for FcγRIIIa and Variable Antibody-Dependent Cellular Cytotoxicity Activities.
Kurogochi M; Mori M; Osumi K; Tojino M; Sugawara S; Takashima S; Hirose Y; Tsukimura W; Mizuno M; Amano J; Matsuda A; Tomita M; Takayanagi A; Shoda S; Shirai T
PLoS One; 2015; 10(7):e0132848. PubMed ID: 26200113
[TBL] [Abstract][Full Text] [Related]
18. Blockade of ErbB2 and PD-L1 using a bispecific antibody to improve targeted anti-ErbB2 therapy.
Mittal D; Vijayan D; Neijssen J; Kreijtz J; Habraken MMJM; Van Eenennaam H; Van Elsas A; Smyth MJ
Oncoimmunology; 2019; 8(11):e1648171. PubMed ID: 31646095
[TBL] [Abstract][Full Text] [Related]
19. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.
Chen N; Fang W; Zhan J; Hong S; Tang Y; Kang S; Zhang Y; He X; Zhou T; Qin T; Huang Y; Yi X; Zhang L
J Thorac Oncol; 2015 Jun; 10(6):910-23. PubMed ID: 25658629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
